TRIB — Trinity Biotech Cashflow Statement
0.000.00%
Last trade - 00:00- $1.64m
- $97.23m
- $61.56m
- 14
- 72
- 37
- 35
Annual cashflow statement for Trinity Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.39 | 0.875 | -41 | -24 | -31.8 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 28.9 | 13.8 | 39.4 | 13.1 | 20.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.83 | -4.15 | -1.68 | -2.38 | 5.08 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 23.8 | 13.2 | -0.921 | -11.6 | -4.19 |
| Capital Expenditures | -10.2 | -8.69 | -5.98 | -2.7 | -10.1 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | 0 | — | 27.5 | -12.9 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -10.2 | -8.69 | -5.98 | 24.8 | -23 |
| Financing Cash Flow Items | -4 | -4.84 | -13.7 | -8.67 | -6.25 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -2.72 | -6.02 | -12.3 | -16 | 28.8 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 10.9 | -1.42 | -19.3 | -2.89 | 1.48 |